134 related articles for article (PubMed ID: 29728928)
1. Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes.
Byeon JY; Lee YJ; Kim YH; Kim SH; Lee CM; Bae JW; Jang CG; Lee SY; Choi CI
Arch Pharm Res; 2018 May; 41(5):564-570. PubMed ID: 29728928
[TBL] [Abstract][Full Text] [Related]
2. Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects.
Jung EH; Lee CM; Byeon JY; Shin HB; Oh KY; Cho CK; Lim CW; Jang CG; Lee SY; Lee YJ
Arch Pharm Res; 2020 Sep; 43(9):976-981. PubMed ID: 32661920
[TBL] [Abstract][Full Text] [Related]
3. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans.
Kim KA; Park IB; Park JY
Eur J Clin Pharmacol; 2018 Oct; 74(10):1281-1289. PubMed ID: 29947950
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects.
Zheng T; Su CH; Zhao J; Zhang XJ; Zhang TY; Zhang LR; Kan QC; Zhang SJ
Pharmazie; 2013 Apr; 68(4):257-60. PubMed ID: 23700791
[TBL] [Abstract][Full Text] [Related]
6. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele.
Cho CK; Kang P; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
Arch Pharm Res; 2021 Nov; 44(11):1037-1049. PubMed ID: 34751931
[TBL] [Abstract][Full Text] [Related]
8. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG
J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141
[TBL] [Abstract][Full Text] [Related]
11. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine.
Byeon JY; Lee CM; Lee YJ; Kim YH; Kim SH; Jung EH; Chae WK; Lee YJ; Jang CG; Lee SY
Arch Pharm Res; 2019 Feb; 42(2):182-190. PubMed ID: 30542809
[TBL] [Abstract][Full Text] [Related]
13. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype.
Molden E; Johansen PW; Bøe GH; Bergan S; Christensen H; Rugstad HE; Rootwelt H; Reubsaet L; Lehne G
Clin Pharmacol Ther; 2002 Sep; 72(3):333-42. PubMed ID: 12235455
[TBL] [Abstract][Full Text] [Related]
15. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
[TBL] [Abstract][Full Text] [Related]
16. Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.
Liu R; Gong C; Tao L; Yang W; Zheng X; Ma P; Ding L
Eur J Pharm Sci; 2015 Nov; 79():13-9. PubMed ID: 26360837
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects.
Trivedi A; Malik FI; Jafarinasabian P; Zhang H; Flach S; Abbasi S; Dutta S; Lee E
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):185-193. PubMed ID: 34145992
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.
Bae JW; Oh KY; Yoon SJ; Shin HB; Jung EH; Cho CK; Lim CW; Kang P; Choi CI; Jang CG; Lee SY; Lee YJ
Arch Pharm Res; 2020 Nov; 43(11):1207-1213. PubMed ID: 33247397
[TBL] [Abstract][Full Text] [Related]
20. Effects of CYP2D6 *10 and *41 Variants in Healthy Chinese Men on the Pharmacokinetics of Dapoxetine.
Wang Z; Gao Y; Ji X; Wu T; Pu L; Qiu W
J Clin Pharmacol; 2024 May; 64(5):601-608. PubMed ID: 38059315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
